Predix, Amgen to collaborate on development of S1P1 modulators for autoimmune diseases

By Lisa Kerner

Charlotte, N.C., July 31 - Predix Pharmaceuticals Holdings, Inc. and Amgen Inc. have agreed to develop and license novel, orally available S1P1 modulators for the treatment of multiple autoimmune diseases, such as multiple sclerosis, type 1 diabetes and rheumatoid arthritis.

Amgen will be responsible for clinical development and commercialization of the product candidates.

Predix will receive an upfront payment of $20 million and up to an additional $387.5 million in milestone payments plus royalties on future sales of products resulting from this collaboration. In addition, the agreement gives Predix the option to promote a product resulting from this collaboration for a selected indication to specialty physicians in the United States.

"This collaboration provides Predix with the option to transform into a fully integrated pharmaceutical company by exercising our co-promote option with Amgen," chief business officer Chen Schor said in a company news release.

"This deal comes as we are in the process of finalizing our merger with EPIX and will further enable the combined company to pursue this research program along with our other development programs."

Predix, a Lexington, Mass.-based pharmaceutical company, recently announced a definitive agreement to merge with EPIX Pharmaceuticals.

Amgen is a pharmaceutical company located in Thousand Oaks, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.